Systemic benefit of radiation therapy via abscopal effect

Daniel J. Craig1, Stephanie Ambrose2, Laura Stanbery2, Adam Walter2,3 and John Nemunaitis2*

1University of Toledo, Department of Internal Medicine, Toledo, OH, United States, 2Medical Affairs, Gradalis, Inc., Carrollton, TX, United States, 3Gynecologic Oncology, Promedica, Toledo, OH, United States

Evidence of a systemic response related to localized radiation therapy (RT) in cancer management is rare. However, enhancing the immune response via immunotherapy followed by localized RT has shown evidence of tumor shrinkage to non-irradiated metastatic disease thereby inducing an “abscopal effect.” Combined induction of the cGAS-STING pathway and activation of IFN-gamma signaling cascade related to RT within an activated immune environment promotes neoantigen presentation and expansion of cytotoxic effector cells enabling enhancement of systemic immune response. A proposed mechanism, case examples, and clinical trial evidence of “abscopal effect” benefit are reviewed. Results support strategic therapeutic testing to enhance “abscopal effect.”

KEYWORDS

abscopal effect, irradiation, cancer management, immune response, autologous tumor immunotherapy, radiation therapy

Abbreviations: AFP, alpha-fetoprotein; ATM, ATM serine/threonine kinase; CCL2, C-C Motif Chemokine Ligand 2; CCL22, C-C Motif Chemokine Ligand 22; cGAMP, cyclic guanosine monophosphate-adenosine monophosphate synthase; cGAS, cGAMP synthase; CIRT, carbon-ion radiation therapy; CR, complete response; EBRT, external beam radiation therapy; Flt3-L, Fms Related Receptor Tyrosine Kinase 3 Ligand; Gy, grey; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; IFI16, interferon gamma inducible protein 16; IMRT, intensity modulated radiotherapy; MDM2, MDM2 proto-oncogene; MHC, major histocompatibility complex; OS, overall survival; PARP-1, poly ADP-ribose polymerase 1; PFS, progression-free survival; PIVKA-II, protein induced by vitamin K absence or antagonists II; RFS, recurrence-free survival; SBRT, stereotactic body radiation therapy; STING, stimulator of interferon genes; TGFβ, transforming growth factor beta; TNF, tumor necrosis factor; TRAF6, TNF receptor associated factor 6; TP53, tumor protein P53; WBRT, whole-brain radiotherapy; XRT, radiation therapy.
Introduction

The abscopal effect is a phenomenon seen when irradiation at a distinct anatomic site induces a systemic antitumor response throughout the body. It was first described using cell lines and was known as the "bystander effect." Researchers found that in addition to direct cellular damage via reactive oxygen and nitrogen species induced by radiation therapy (RT), irradiated cells could also induce changes in distant non-irradiated cells through cell signaling molecules (1). Initial studies demonstrated that cell culture media taken from irradiated cultures could be transferred to non-irradiated cultures and induce DNA damage (1). Similarly, tumor cells can elicit cellular and DNA changes within normal cells when media used to grow tumor cells is transferred to normal cultures. This conditioned media demonstrates increased levels of many cytokines including transforming growth factor beta (TGFβ) and C-C Motif Chemokine Ligand 2 (CCL2) (2, 3). In addition, in vivo experiments using both C57BL/6 wild-type and CCL2-knockout mice subjected to ionizing radiation identified six differentially expressed genes implicated in the abscopal effect in tissue outside the field of radiation. These include TGFβ (4) and CCL2 (5), as well as tumor protein P53 (TP53) (6), tumor necrosis factor (TNF) (7), C-C Motif Chemokine Ligand 22 (CCL22) (8), and the proto-oncogene, MDM2 (9).

CCL2 is particularly important, as it is involved in the propagation of the immune effects associated with abscopal activity. Specifically, CCL2 is a member of the monocyte chemoattractant protein family and not only serves an important role in the recruitment of monocytes, but also has been shown to recruit T cells, B cells, NK cells, macrophages, and dendritic cells (10–14). It is induced by multiple pro-inflammatory molecules (15–18) and by reactive oxygen and nitrogen species generated by RT supporting the idea that it contributes significantly to the immune response associated with the abscopal effect (19).

While the precise mechanism for the abscopal effect is complex and continues to be elucidated, current evidence supports that it is primarily a T cell-mediated process. Ultimately, irreparable DNA damage in tumor cells induced by RT increases tumor immunogenicity by providing dendritic cells with tumor-specific antigens to present to, and activate, CD8+ T cells via major histocompatibility complex (MHC) class I. Clinical case examples, which we summarize, have stimulated ongoing preclinical and clinical trials focusing on strategies to stimulate dendritic cell proliferation and T cell activation to more consistently induce an abscopal effect concurrent with RT.

In an effort to understand abscopal activity, we can look at the molecular mechanism behind RT-induced DNA damage and the immune response. Specifically, RT of tumor cells induces double-stranded DNA breaks and unique nucleotide adducts that leak into the cytosol and bind to the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) protein resulting in an increase in intracellular cGAMP (20, 21). Increasing levels of cGAMP then bind to the stimulator of interferon genes (STING) protein leading to the production of type 1 interferons (IFN-1). (IFN-1 binds to IFNAR1/2 receptors that result in a signaling cascade that activates immune-stimulating genes that promote activation of dendritic cell populations (22).

However, in addition to the anti-tumor and immunogenic effects of the cGAS-STING pathway, this pathway has also been shown to induce pro-tumorigenic factors, such as IL-6 through activation of the NFκB pathway and PD-L1 through activation of the JAK-STAT pathway (23, 24). This is important in the context of induction of abscopal effect because IL-6 has been implicated in resistance to RT by suppressing oxidative stress, and efforts to pharmacologically block the production of IL-6, in addition to PD-L1, may help increase the abscopal effect (25). In addition to the canonical cGAS-STING pathway, an alternative STING pathway is also capable of sensing DNA damage independent of the cytosolic DNA receptor cGAS. Instead, this non-canonical STING pathway utilizes a protein complex consisting of a DNA binding protein called Interferon Gamma Inducible Protein 16 (IFI16), DNA damage response factors (ATM serine/threonine kinase [ATM] and Poly ADP-Ribose Polymerase 1 [PARP-1]), tumor suppressor protein p53 (TP53), and a E3 ubiquitin ligase called TNF Receptor Associated Factor 6 (TRAF6). This protein complex ultimately leads to the activation of the NFκB pathway resulting in expression of IFN-β and thus its downstream targets (26). Each of these unique pathways demonstrates the complexity of RT-induced DNA damage and the diverse molecular mechanisms that play a role in both anti-cancer and pro-cancer response.

Importantly, as the dose of radiation increases, larger amounts of damaged DNA products precipitate in the cytosol activating TREX1, a cytosolic DNA exonuclease that functions to degrade and eliminate cytosolic DNA, precluding the activation of the cGAS-STING signaling cascade that is thought to trigger the abscopal effect. In an effort to fine-tune induction of abscopal effect, Vanpouille-Box et al. sought to determine an optimal radiation dose that maximized production of IFN-1 while minimizing TREX1 expression using a mammary carcinoma mouse model treated with RT and an antibody against anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). CTLA-4 is a cell-surface protein expressed by regulatory T cells to inhibit T cell functions by increasing the activation energy necessary for T cell cell activation (27). This is especially important in the context of cancer due to the weakly immunogenic self- and tumor-antigens. Ipilimumab is an anti-CTLA-4 antibody and was the first immune checkpoint inhibitor approved for treating cancer (28, 29). Their results showed that
an irradiation scheme of 8 grey (Gy) x 3 coupled with an anti-CTLA-4 antibody did not result in TREX1 gene expression, while a single large dose (20 and 30 Gy) coupled with an anti-CTLA-4 antibody did (30). Activation of IFN-1 was preserved in both examples.

In addition to optimizing expression of both immune-stimulating and immune-suppressing genes, several studies have demonstrated the importance of an intact T cell response and a sufficient dendritic cell population to induce an abscopal response. For example, Stone et al. published one of the first preclinical experiments seeking to understand the abscopal effect using a syngeneic fibrosarcoma mouse model. They showed that the radiation dose necessary to reduce tumor size by 50% was significantly smaller in T cell-competent mice compared to T cell-depleted mice. In addition, they noticed that the likelihood of metastasis was lower in T cell-competent mice compared to their T cell-depleted counterparts (31). More recently, Demaria et al. utilized a murine model with both wild-type and nu/nu T cell-deficient BALB/C mice to compare (a) the effect of irradiation alone or irradiation supplemented with the dendritic cell stimulator, Fms-Related Receptor Tyrosine Kinase 3 Ligand (Flt3-L), and (b) the effect of tumor immunogenicity using two cell lines (32). The two groups of mice were injected at two distinct anatomic sites with either the highly immunogenic 67NR BALB/C mouse-derived mammary carcinoma cell line or the low immunogenicity A20 BALB/C mouse-derived B-cell leukemia/lymphoma cell line creating a pseudo-primary site that would receive direct RT (2 Gy, single dose) and a secondary site that would not. Their results showed that not only were T cells necessary to induce a response at the secondary, non-irradiated site, the addition of Flt3-L significantly increased the tumor response at the non-irradiated site in the wild-type mice. In addition, the low immunogenicity A20 B cell leukemia/lymphoma cell line did not show a significant increase in response at the secondary site in both the irradiation alone and irradiation + Flt3-L groups demonstrating the importance of an immunogenic tumor in activating a T cell response.

The combination of RT with immune checkpoint inhibition (ICI)—pharmacologic agents has also resulted in a more potent tumor response than either treatment alone in preclinical studies examining head and neck cancer, metastatic melanoma, metastatic pancreatic cancer, and lung cancer (33–35). This has resulted in investigators examining ideal radiation dosing and fractionation schemes when coupled with ICI to induce abscopal responses. For example, Dewan et al. utilized a mouse model of bilateral mammary adenocarcinoma to identify an ideal radiation dose. In their study, they treated mice with either 3 fractions (8 Gy each) coupled with an anti-CTLA-4 monoclonal antibody (mAb), or a single dose (30 Gy) coupled with the anti-CTLA-4 mAb. Their results showed an abscopal response in the group treated with 8 Gy x 3 + anti-CTLA-4 mAb but did not see the same response in the group treated with a single dose of RT (30 Gy) coupled with the anti-CTLA-4 mAb (36).

### Clinical case reports of abscopal effect following irradiation without systemic treatment

Early evidence of abscopal activity has initially been portrayed in published case reports which are described below. Each demonstrate systemic clinical response following local site RT as consistent with abscopal activity.

A 57-year-old male was diagnosed with multiple lung nodules, vertebra metastases, and brain metastases (37). The results of pathological examination suggested adenocarcinoma of the lung. RT of 39 Gy in 13 fractions was administered to the ninth thoracic vertebra for destructive extension. However, all the lesions including the brain metastases spontaneously shrunk, thereby supporting abscopal activity as no systemic therapy had been administered. Two months after RT, complete regression to the lung and other non-irradiated thoracic vertebra was achieved. Whole-brain radiotherapy for a total dose of 36 Gy in 12 fractions was performed. Unfortunately, 15 months after initial RT, the brain metastasis recurred.

A 61-year-old male with renal cell carcinoma and metastatic lesions to the brain, bone, spine, lung, and lymph nodes underwent stereotactic body radiation therapy (SBRT) to the brain metastases and external beam radiation therapy (EBRT) to the metastatic lesions in his bone and spine (38). 1 month later, lesions that were not subjected to radiotherapy showed regression as evidenced by CT scan. In addition, follow-up CT scans taken 2 months later and 3 months later demonstrated continued response of these untreated lung lesions suggesting a possible abscopal response. Unfortunately, this patient went on to develop new brain metastases requiring additional stereotactic radiosurgery.

A 66-year-old female with clear cell renal cell carcinoma was treated with a nephrectomy (39). Ten years later, the patient had a metastatic lesion of the renal cell cancer in the neck, and was treatment with pazopanib, but then terminated due to intolerability. CT scans of the thorax and the neck showed progression in the neck, portacaval lymph node, hyphochondrium subcutaneous node, and new and progressive lung metastases. Palliative RT was given to the neck, but the patient did not resume systemic therapy. Eleven months after (radiation therapy) XRT, the patient had complete regression of the lung metastases, the subcutaneous abdominal node remained, but growth of the portacaval lymph node persisted. 17 months after XRT, the patient’s stable disease remained, demonstrating abscopal activity.

A 93-year-old female with melanoma on the fifth metatarsal (Breslow depth: 2.8 millimeters) underwent therapeutic
amputation. Despite amputation, the patient demonstrated disease progression 13 months later. He presented with a 4-centimeter painful inguinal lymph node mass along with 5 cutaneous nodules located on the anterolateral leg below the knee. These cutaneous nodules were hard to palpation and macroscopically consistent with metastasis. The patient underwent palliative RT to the inguinal lymph node for pain management. Interestingly, the patient also demonstrated near complete resolution of the non-irradiated cutaneous lesions one month after RT. The patient was lost to follow-up 14 months later due to relocation to a new city, but demonstrated stable disease throughout that period (40).

A 75-year-old male with a history of stage IV colorectal cancer with liver metastasis (November 2007) status post anterior resection with partial hepatectomy and rectal cancer (January 2010) status post anterior resection presented with abdominal pain in November 2010. Abdominal imaging showed two masses: a 35-millimeter mass located on the left side of the abdomen and a 15-millimeter mass invading the right common iliac artery. The left-sided mass was irradiated using carbon-ion radiation therapy (CIRT) with a regimen of 73.6 Gy x 16 fractions over a 28-day period in January 2011. The mass invading the right common iliac artery was not irradiated due to its proximity to the small intestine. Interestingly, a PET-CT scan performed 1 month after therapy showed significant reduction in tumor size in both the irradiated and non-irradiated tumors as evidenced by decreased fluodeoxyglucose accumulation. Unfortunately, the patient died 46 months after CIRT due to myelodysplastic syndrome with no evidence of abscopal response to CIRT (41).

An 85-year-old male with a history of recurrent colon cancer in the ascending colon presented with back pain in February 2009 after a 10-month stable period post hemicolectomy (April 2008). CT imaging revealed a 45-millimeter para-aortic tumor along with two 10-millimeter tumors in the mediastinum and right clavicle. The patient was not eligible for chemotherapy due to comorbidities, so the decision was made to perform CIRT (Gy x 12 fractions over 21 days) on the para-aortic mass as part of an ongoing clinical trial. Following completion of therapy, there was a significant reduction in size of the irradiated para-aortic tumor as well as the non-irradiated mediastinal and subclavian tumors as evidenced by both CT and PET-CT imaging. The patient received no additional therapy, which suggests the patient had an abscopal response to CIRT. The patient’s condition has remained stable for 92 months at the time of publication with no change in tumor size (41).

A 63-year-old male presented with a 10.5 cm x 9 cm x 11 cm hepatocellular carcinoma (HCC) with 3 daughter nodules <1 centimeter each. He underwent an extended right lobectomy and was stable for 18 months until metastatic nodules were found in the right lower lobe of the lung and left mediastinal lymph node as evidenced by CT scan. This was confirmed to be HCC metastatic disease due to an alpha-fetoprotein (AFP) of 4,869 ng/mL and a protein induced by vitamin K absence or antagonists II (PIVKA-II) >20,000 mAU/mL. Trans-catheter arterial embolization of the mediastinal tumor was attempted but ultimately aborted due to risk of spinal artery embolism. The decision was made to perform palliative external beam radiation therapy (2.25 Gy x 27 fractions) on the mediastinal node. Following RT, both the mediastinal lymph node and the right lower lobe lung tumor demonstrated significant response as evidenced by CT scan along with a decrease in AFP from 4,869 ng/mL to 23 ng/mL and a decrease in PIVKA-II from >20,000 mAU/mL to 13 mAU/mL. His disease remained stable for 4 years until a 3.5 cm lymph node was found near the left gastric artery. He was treated with stereotactic body radiotherapy and showed no additional disease after 6 months (42).

A 76-year-old female was diagnosed with pulmonary adenocarcinoma (cT1bN0M0) in November 2015, and subsequently underwent a right upper lobectomy with confirmation of pathological pT1bN2M0, stage IIIA disease. The patient did not receive adjuvant chemotherapy. In February 2018, multiple new mediastinal and right hilar lymph node metastases were identified. A total dose of 60.0 Gy of RT was given over 6 weeks to selected lesions. The target area included multiple mediastinal, and several (but not all) right hilar lymph nodes. Twelve weeks after completion of RT, a chest CT scan showed complete disappearance of the treated and untreated pulmonary metastases. Another follow up CT scan was completed (6 months after completion of RT) showing no reappearance of multiple metastatic pulmonary nodules both non irradiated and irradiated pulmonary nodules supportive of abscopal effect (43).

An 81-year-old female was diagnosed with a pT2a, pN0 (0/5), cM0, UICC stage IB squamous cell carcinoma of the left upper lung lobe (44). She underwent a lobectomy with lymphadenectomy, and subsequently had no relapse for 5 years during follow up. Thirteen years later, recurrence was confirmed via biopsy, chest CT showed a mass in the left lung, negative for brain metastasis on MRI, and PET showing left sided pleural carcinomatosis, left sided periclavicular lymph node metastases, and bone metastases in the 12th thoracic and 4th lumbar vertebra. The patient declined systemic treatment. She thus underwent palliative radiotherapy to the symptomatic pulmonary tumor. Four weeks after RT completion, restaging was performed showing a partial remission of the tumor, the nodal metastases and the previously untreated vertebral lesions. During follow-up, further decrease in tumor size and complete metabolic remission of the bone, pleural and lymph node metastases was seen. 25 months after radiotherapy, the patient still had evidence of stable disease, but remained free of disease symptoms.

In June 2018, a 69-year-old male was diagnosed with squamous cell carcinoma of the right lower lobe with
involvement of mediastinal nodes (45). The patient was initially treated with vinorelbine and cisplatin however, after four cycles, his symptoms worsened, and chest CT scan confirmed progressive disease. Hence, the chemotherapy regimen was shifted to paclitaxel, but the primary lung lesion was still not controlled, and he showed disease progression in the chest, and as well as a bone scan that showed a new lesion in the right tibia, indicating the occurrence of bone metastases. After initial response, this patient showed progression on the PD-1 inhibitor, camrelizumab, and the tyrosine kinase inhibitor that selectively inhibits VEGFR2, apatinib, and went on to receive palliative CT-guided microwave ablation to the primary lung tumor. One month later, chest CT scan showed the right lower lobe mass and mediastinal lymph nodes were also reduced, indicating an abscopal effect following local ablation.

These cases highlight systemic abscopal effect related to localized RT. The effect involved a broad range of cancer patients that include a robust age range up to 93 years old.

**Case reports of abscopal effect with irradiation and enhancing immune modulation**

Evidence of abscopal activity related to systemic immune induction of RT may be enhanced with combination immune modulatory therapy. The following case reports support evidence of abscopal activity with combined RT in a setting of failed systemic response prior to ongoing immunotherapy followed by immune response with same immune therapy (absopal effect) after local RT.

A 54-year-old male patient presented with a stageT4N0M1b disease. He had a pulmonary large cell neuroendocrine carcinoma of the right upper lobe, associated with bilateral adrenal metastases and a PD-L1 tumor proportion score of 20% (46). After four cycles of chemotherapy (pemetrexed, cisplatin) and the VEGF inhibitor, bevacizumab, CT scans revealed disease progression in the right upper lobe as well as in both adrenal glands. Second-line therapy with nivolumab, a PD-1 inhibitor, was started, but increasingly symptomatic spinal cord compression, due to tumor invasion occurred. Hemilaminectomy of the third thoracic vertebra combined with resection of the epidural tumor mass was thus performed. Postoperative radiotherapy (30 Gy) was applied targeting the involved thoracic vertebrae. Nivolumab continued, CT scans 4 months after the first radiotherapy showed partial regression of the lung tumor and adrenal metastases. The patient showed disease progression 10 months after radiotherapy but is still alive, supportive of abscopal effect, 25 months after the initial diagnosis.

A 70-year-old male patient presented with a T3N2M1a disease involving central adenocarcinoma of the middle lung lobe, associated with positive mediastinal lymph nodes and a malignant ipsilateral pleural effusion. There were no EGFR or ALK mutations and the PD-L1 tumor proportion score was 70%. First-line therapy with pembrolizumab, a PD-1 inhibitor, was started, leading to a partial response. After a year of treatment, pulmonary and pleural disease progression occurred, and a clinically symptomatic brain metastasis associated with perimetastatic cerebral edema appeared. Pembrolizumab was continued and WBRT added (30 Gy in ten fractions). Radiography of the thorax after radiotherapy showed partial regression of the lung tumor and pleural effusion, supportive of abscopal activity. The patient is still alive 19 months after the initial diagnosis (46).

A 65-year-old female patient presented with mucosal melanoma in June 2015 with no evidence of metastatic disease as evidenced by CT scan of the neck and MRI with gadolinium. The decision was made to perform a right partial maxillectomy to remove the lesion followed by targeted intensity modulated radiotherapy (IMRT). Unfortunately, the patient relapsed 9 months later, and evidence of disease progression was found in the neck and lungs. The patient was then enrolled in a trial comparing epacadostat + pembrolizumab or placebo + pembrolizumab, which initially
showed tumor response, but ultimately resulted in disease progression. The treatment was stopped, and the patient started a palliative course of IMRT to the neck due to increased symptoms. Interestingly, both the neck lesion and the pulmonary lesions responded to IMRT based on CT scans before and after IMRT suggesting an abscopal response (47).

A 67-year-old female presented with metastatic pancreatic uncinate carcinoma to the right liver lobe in August 2015 with a CA 19-9 of 1,814 U/mL. The patient was initially treated with single-agent gemcitabine, but this was discontinued due to poor response and worsening abdominal pain. The patient was then switched to albumin-bound paclitaxel, which demonstrated partial response based on Response Evaluation Criteria in Solid Tumors (RECIST 1.0), but ultimately demonstrated disease progression with additional metastasis to the right pleura and worsening side effects. The patient was then switched to Apatinib, but this was quickly discontinued due to severe gastrointestinal distress. The decision was made to initiate palliative radiotherapy (45 Gy x 15 over 3 weeks) coupled with GM-CSF to the primary pancreatic tumor due to abdominal pain and jaundice requiring percutaneous transhepatic-cholangial drainage. 1 month later, the patient demonstrated significant response to the primary tumor as evidenced by CT scan, but also demonstrated significant abscopal response to the metastatic sites in the liver and pleura that were outside the cone of radiation (48).

A 33-year-old female presented with a mole on her upper back concerning for melanoma in April 2004. Biopsy of the lesion revealed melanoma with a Breslow thickness of 1.53 millimeters. The decision was made to perform a wide local excision of the malignant lesion along with sentinel lymph node biopsy. The patient remained disease free until 2008 when a PET-CT revealed a 2-centimeter pulmonary nodule suggestive of metastatic disease that was confirmed via CT percutaneous biopsy. She was treated with cisplatin, vinblastine, and temozolomide (CVT) chemotherapy due to lack of a targetable mutation (e.g., BRAF) followed by surgical resection. The patient demonstrated stable disease until surveillance CT scan showed a metastatic paraspinal mass along with hilar lymphadenopathy in August 2009. The decision was made to initiate 4 doses of ipilimumab, a CTLA-4 inhibitor, (10 mg/kg) every 3 weeks which resulted in an initial slight enlargement of the paraspinal mass but effectively stabilized her disease for 14 months. Unfortunately, the patient demonstrated continued enlargement of the paraspinal mass with additional evidence of metastatic splenic lesions. The patient was experiencing significant back pain due to mass effect from the paraspinal mass, so the decision was made to initiate palliative RT to the paraspinal mass (950 Gy x 3 fractions over 7 days). Ten months after therapy, there was evidence of abscopal effect as evidenced by CT-scan demonstrating significant reduction in size of both the treated paraspinal mass and the splenic lesions that were outside the cone of radiation (49).

A 71-year-old male was diagnosed with stage IV lung adenocarcinoma, and began treatment with atezolizumab (50). After 19 months of atezolizumab, there was a complete response to the primary lung tumor. A brain metastasis then developed two years later, which was treated with gamma knife radiotherapy. However, after radiation, the patient’s lung disease recurred. Two months later, the lesions in the lung had shrunk, indicating that the

---

### TABLE 1 Abscopal case reports following irradiation without systemic treatment.

| Patient | Disease | Sites of involvement | Treatment | Response | Reference |
|---------|---------|----------------------|-----------|----------|-----------|
| 57-year-old male | Unknown primary | Lung nodules, vertebra, and brain metastases | Radiation (XRT) to 9th vertebra | All lesions | (37) |
| 61-year-old male | Renal Cell carcinoma | Bone, spine, brain, lung lymphadenopathy | XRT to brain, spine, and bone | Regression of untreated lung metastases and lymphadenopathy | (38) |
| 66-year-old female | Renal Cell carcinoma | Neck, lung and portacaval node | XRT to the neck | Regression of irradiated neck mass and non-irradiated lung metastases | (39) |
| 93-year-old female | Melanoma (toe) | Thigh and inguinal node | Surgery, RT to inguinal region | Regression of thigh lesions | (40) |
| 75-year-old male | Colorectal cancer | Liver mets | Resection and RT | Reduction in both the treated and untreated liver masses | (41) |
| 85-year-old male | Colorectal Cancer | Nodes (near abdominal aorta, mediastinal, and subclavian) | Resection and XRT to aortic lymph node | Untreated subclavian node shrank, and mediastinal node remained stable. | (41) |
| 63-year-old male | Hepatocellular Carcinoma | Lung and mediastinal nodes | XRT to mediastinal lymph node | Mediastinal lymph node and untreated lung mass | (42) |
| 76-year-old female | NSCLC | Mediastinal and hilar lymph nodes, lung disease | XRT only, to mediastinal and hilar lymph nodes. | Complete response to multiple untreated lung lesions | (43) |
| 81-year-old female | NSCLC | Lung, pleura, periclavicular node, and vertebra | XRT only | Complete remission of untreated vertebral lesions and periclavicular node | (44) |
prior changes in the lung may have been pseudo-progression as abscopal effect was later demonstrated.

Combination irradiation with immunotherapy may be associated with more frequent abscopal effect as suggested by preclinical testing and preliminary clinical results (31–36, 51). In summary (see Tables 1, 2), these 17 case reports provide evidence of abscopal effect and support combination with immunotherapy is well tolerated and may enhance abscopal activity related to RT.

Current studies evaluating abscopal effect

The clinical trial landscape for abscopal effect and development of clinical trials is increasing. There are several prospective clinical trials investigating the abscopal effect (Table 3). However, consistent results regarding occurrence of abscopal effect and level of benefit are highly variable. Moreover,

| TABLE 2 | Abscopal case reports of irradiation and systemic treatment following systemic treatment failure. |
|---------|------------------------------------------------------------------------------------------------------------------|
| Patient | Disease | Sites of involvement | Treatment | Response | Reference |
|---------|---------|----------------------|-----------|----------|-----------|
| 69-year-old male | NSCLC | Lung, mediastinal and other nodes | Vinorelbine/cisplatin, paclitaxel, camrelizumab/apatinib, CT-guided microwave ablation of lung lesion, following systemic treatment failure | After progression on systemic treatment and then XTR, right lower lobe mass and mediastinal lymph nodes reduced | (45) |
| 54-year-old male | Neuroendocrine | Lung, adrenal glands, paraspinal cord | After progression with systemic therapy, Pemetrexed/cisplatin/bevacizumab, nivolumab, XRT to para spinal vertebrae | Lung tumor and adrenal metastases underwent regression | (46) |
| 64-year-old male | NSCLC | Mediastinal contralateral lymph nodes and distant metastases (brain and ocular) | Nab-paclitaxel/carboplatin/atezolizumab, atezolizumab alone, after progression of all lesions, WBRT (whole brain radiation therapy) | PR to brain, CR to lung and mediastinal masses was seen after WBRT | (46) |
| 70-year-old male | NSCLC | Mediastinal lymph nodes and malignant pleural effusion, PD-L1 70% | Failed Pembrolizumab, then WBRT added | Partial regression of the lung tumor and pleural effusion after WBRT | (46) |
| 65-year-old female | Melanoma (mucosal) | Neck and pulmonary mets | Failed Pembrolizumab, then given XRT to neck | Tumor regression of the pulmonary metastases after XRT to the neck | (47) |
| 67-year-old female | Pancreas Cancer | Liver and right pleura | Failed Gemcitabine, paclitaxel, apatinib, then given palliative XRT (to pancreas)/GM-CSF | XRT to pancreatic tumor, non-irradiated systemic metastases significantly decreased | (48) |
| 33-year-old female | Melanoma (cutaneous) | Pulmonary nodule, paraspinal mass, hilar node, splenic lesion | Failed Cisplatin/vinblastine/temozolomide (CVT), spimulumb, XRT to paraspinal mass | Regression to non-irradiated hilar lymphadenopathy and splenic lesions | (49) |
| 71-year-old male | NSCLC | Brain mets, mediastinal lymph nodes lung disease | Failed nedaplatin/paclitaxel, and Atezolizumab, then given Atezolizumab/brain XRT | Primary lung lesion and hydrothorax decrease after systemic treatment failure and brain XRT | (50) |

| TABLE 3 | Select ongoing clinical trials involving radiotherapy and checkpoint inhibitors to achieve abscopal effect. |
|---------|------------------------------------------------------------------------------------------------------------------|
| Cancer type | Irradiation scheme/comboination | Clinical trial number |
|---------|------------------------------------------------------------------------------------------------------------------|----------------------|
| NSCLC | 30-50 Grays in 5 fractions Bevacizumab toripalimab | NCT04238169 |
| NSCLC | 20 Gray nivolumab | NCT03480334 |
| NSCLC | 20 x 2 Gray (daily for 4 weeks) 5 x 5 Gray (daily over 1 week) 3 x 8 Gray (every other day over 1 week) Durvalumab | NCT04245514 |
| Metastatic Cancer | 1 dose of SBRT Durvalumab and tremelimumab | NCT03212469 |
| Hepatocellular | 4 fractions over 8-15 days Pemtrulizumab | NCT03316872 |
trials exploring expansion of abscopal effect looking at various irradiation doses, schedules and immune modulating combination therapy still only provide relatively low occurrence rate of abscopal activity. In general, though, when abscopal effect is observed compared to those receiving the same regimen without abscopal effect clinical benefits with respect to response, progression-free survival (PFS) and overall survival (OS) is observed (52–54). In one early retrospective study involving melanoma patients treated with ipilimumab followed by RT, 52% showed evidence of abscopal activity and those who did had significantly improved OS (54). Another retrospective study involving melanoma showed similar results (55). Moreover, in a third small trial of 10 prostate cancer patients improved durable disease control was observed with combined ipilimumab and irradiation (56). Although in a larger later Phase 3 trial of advanced prostate cancer undergoing irradiation and ipilimumab vs. irradiation alone OS was not different (57).

Similarly, several combination PD-1/PD-L1 checkpoint inhibitor treatments with RT have also demonstrated evidence of abscopal activity. KEYNOTE-001 trial demonstrated improved PFS and OS in NSCLC patients who received prior RT and pembrolizumab compared to pembrolizumab alone although actual abscopal events were not well defined (58). Another retrospective study looking at PD-1 inhibitors involving melanoma patients, some receiving RT, showed significant improvement in response rate but no improvement in PFS and OS with combination checkpoint inhibitors/RT. However, only one patient of 59 demonstrated abscopal activity (59). Not all clinical results have reproduced the same

Consideration GM-CSF expression/ TGFβ knockdown to induce abscopal effect

There continues to be strong evidence that radiation is able to activate the immune system although the mechanism for this has not been fully elucidated (62). RT has also been shown to promote the development of an immunosuppressive tumor microenvironment, specifically by upregulation of PD-L1 (64, 65). Therefore, it has been hypothesized that radiation coupled with immunotherapy would elicit an abscopal effect. However, results have been limited with studies evaluating the dose of radiation and sequencing of combination immunotherapy (66). The abscopal effect has largely been observed in highly immunogenic tumors including melanoma, renal cell, and hepatocellular carcinoma. The tumor microenvironment in these “hot” tumor types are characterized by T cell infiltration and expression of proinflammatory cytokines (67).

In addition to combination with checkpoint inhibitor therapy, autologous tumor cellular immunotherapy may also be considered as a clinical testing direction. Vigil is a triple function immune therapy constructed from patient tumor cells. Vigil mechanism involves the introduction of bifunctional short-hairpin RNA to knockdown furin in the autologous tumor cells. Furin knockdown results in decreased cleavage of TGFβ into TGFβ1 and TGFβ2 (68). TGFβ is an immune suppressive cytokine associated with poor prognosis and therapeutic resistance in many solid tumors (69–71). Vigil plasmid also encodes for human GM-CSF which is also an immune stimulatory cytokine that increases tumor antigen presentation by dendritic cells (72). Moreover, Vigil provides personalized, clonal cancer specific neoantigens to enable the immune system to recognize tumor cells and mount an effective, targeted T-cell mediated response. Vigil has demonstrated improved clinical outcomes which correlated with IFNγ-ELISPOT positivity (73, 74). IFNγ is known to activate a multitude of immune cells, including effector T cells. Vigil has shown clinical benefit in advanced solid tumor patients with overall survival correlation with T1S[HIGH] vs. T1S[LOW] (one year OS 75% vs. 25%, p=0.03795) and elevated MHC-II expression (p=0.038). In recurrent ovarian cancer patients, the OS rate was observed to be 58% compared to historical rate of <20% with standard of care. In a Phase Ib double-blind, randomized, placebo-controlled trial in frontline ovarian cancer maintenance, Vigil patients demonstrated a trend towards benefit (11.5 months vs. 8.4 months for placebo, p=0.078). The result for the secondary endpoint of recurrence-free survival (RFS) for the BRCA-wt subpopulation however, was statistically significant, demonstrating benefit in RFS from procurement (time of initial debulking surgery) and
randomization (time of initial Vigil administration; 18.3 months vs. 14.8 months, HR=0.478, p=0.02; 11.5 months vs. 8.0 months, HR=0.514, p=0.02 respectively) and OS from procurement and randomization (not reached vs. 48.3 months, HR=0.490, p=0.047; not reached vs. 41.4 months, HR=0.493, p=0.049 respectively). Based on a post hoc exploratory analysis in the BRCA-wt, HRP subpopulation, RFS and OS were increased in a statistically significant fashion relative to the control arm, demonstrating a benefit with Vigil in RFS from procurement and randomization (18 months vs. 12 months, HR=0.363, p=0.005; 10.6 months vs. 5.7 months, HR=0.386, p=0.007 respectively) and OS from procurement and randomization (not reached vs. 37.3 months, HR=0.340, p=0.018; not reached vs. 26.9 months, HR=0.342, p=0.019 respectively). Long term follow up analysis also revealed that 83% of Vigil treated patients were still alive three years after their initial debulking surgery versus 40% who received placebo (p=0.0006). Clinical testing of Vigil with RT to induce and augment the abscopal effect is under consideration.

**Conclusion**

Clearly sufficient preclinical and clinical evidence exists which support benefit to patients who incur abscopal effect while undergoing RT. There does not appear to be any concerning toxic effect related to abscopal activity. Benefit associated with response, PFS, duration of PFS and OS has been observed. However, results are inconsistent and hard to predict. Biomarkers indicative of abscopal development are not known. Combination of RT with immune modulatory therapy appear to suggest enhancement in abscopal activity but results are variable. Further research towards enhancement in abscopal activity is warranted. Consideration in modulation of GM-CSF expression and TGFβ knockdown is justified.

**Data availability statement**

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

**Author contributions**

DC, SA, LS, and AW contributed to writing and editing the manuscript. JN was responsible for manuscript conception, supervision and writing and editing. All authors contributed to the article and approved the submitted version.

**Conflict of interest**

Authors SA, LS, AW, and JN were employed by Gradalis, Inc.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**References**

1. Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. *Nat Rev Cancer* (2009) 9(5):351–60. doi: 10.1038/nrc2603

2. Dickey JS, Baird BJ, Redon CE, Sokolov MV, Sedelnikova OA, Bonner WM. Intercellular communication of cellular stress monitored by gamma-H2AX induction. *Carcinogenesis* (2009) 30(10):1686–95. doi: 10.1093/carcin/bgp192

3. Martin OA, Redon CE, Nakamura AJ, Dickey JS, Georgakilas AG, Bonner WM. Systemic DNA damage related to cancer. *Cancer Res* (2011) 71(10):3437–41. doi: 10.1158/0008-5472.CAN-10-4579

4. Vanaousse-Ber C, Diamond J, Redon CE, Sedelnikova OA, Bonner WM. Systemic DNA damage related to cancer. *Cancer Res* (2011) 71(10):3437–41. doi: 10.1158/0008-5472.CAN-10-4579

5. Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. *J Exp Med* (1997) 186(10):1757–62. doi: 10.1084/jem.186.10.1757

6. Camphausen K, Moses MA, Menard C, Sproull M, Beecken WD, Folkman J, et al. Radiation abscopal antitumor effect is mediated through p53. *Cancer Res* (2003) 63(8):1990–3.

7. Stout RD. Macrophage activation by T cells: cognate and non-cognate signals. *Curr Opin Immunol* (1993) 5(3):398–403. doi: 10.1016/0952-7915(93)90005-2

8. Siva S, Lobachevsky P, MacManus MP, Kren T, Moller A, Lobb RJ, et al. Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues. *Clin Cancer Res* (2016) 22(19):4817–26. doi: 10.1158/1078-0432.CCR-16-0138
9. Perry ME, Lobachevsky P, MacManus MP, Kron T, Moller A, Lobbl RJ. Mdm2 in the response to radiation. Mol Cancer Res (2004) 2(1):9–19. doi: 10.1158/1541-7786.2.1

10. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemotactic protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U.S.A. (1994) 91(9):3652–6. doi: 10.1073/pnas.91.9.3652

11. Frae JM, Molero MR, Del Real G, Gutiérrez MC, Jind P, Martínez AC. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in b cells. J Immunol (1997) 159(11):5756–8.

12. Allavena P, Bianchi G, Zhou D, van Damme J, Ilepe P, Sozzani S, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 24(12):3233–6. doi: 10.1002/eji.1830241249

13. Gendelman HE, Ding S, Gong N, Liu J, Ramirez SH, Persidsky Y, et al. Monocyte chemotactic protein-1 regulates voltage-gated k+ channels and macropolyme transmigration. J Neuroimmune Pharmacol (2009) 4(1):47–59. doi: 10.1007/s11481-008-9133-1

14. Zhu K, Shen Q, Ulrich M, Zheng M. Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines. Clin Med Eng J (Eng) (2000) 13(12):1124–8.

15. Van Coillie E, Van Damme J, Opdenakker G. The MCP/monostatin subfamily of CC chemokines. CytoKine Growth Factor Rev (1999) 10(1):61–86. doi: 10.1016/S1359-6101(99)00005-2

16. Kumar SN, Boss JM. Site of a of the MCP-1 distal regulatory region functions as a transcriptional modulator through the transcription factor NF1. Mol Immunol (2000) 37(11):623–32. doi: 10.1016/S0161-5800(00)00997-3

17. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol (2001) 2(2):102–7. doi: 10.1038/84205

18. Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: A foe or ally? Cell Mol Immunol (2016) 13(4):335–45. doi: 10.1038/ cmi.2016.135

19. Sprung CN, Izhakievich A, Forrester HB, Redon CE, Georgakilas A, Martin JF. Nrf2-antioxidant pathway in oral squamous cell carcinoma. Acta Clinica Belgica (2017) 72(4):245–9. doi: 10.1080/17843286.2016.1201614

20. Silva C, Fardilha C, Freitas D, Fonseca G, Louro M, Costa P. Abscopal effect of radiation therapy in monotherapy in patient with malignant melanoma. Appl Radiat Oncol (2019) 4:86–8.

21. Ehrner DK, Kamada T, Yamada S. Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports. Adv Radiat Oncol (2017) 2(3):333–8. doi: 10.1158/2376-7322.adro.2016.07.001

22. Okuma K, Yamashita H, Nibue Y, Hayakawa K. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: A case report. J Med Case Rep (2011) 5:111. doi: 10.1186/1752-1947-5-111

23. Kuroda A, Tabuchi T, Iwashimizu N, Sasaki M, Utsujii K, Nakaizumi M, et al. Abscopal effect of radiation on multiple lung metastases of adenocarcinoma: A case report. BMC Cancer (2019) 19(1):336. doi: 10.1186/s12885-019-5566-8

24. Vilinovskii O, Andratschkle N, Huedler M, Curioni-Fonteado C, Kroeger SC. True abscopal effect in a patient with metastatic non-small cell lung cancer. Radiat Oncol (2019) 16:119. doi: 10.1186/s13014-019-01920-4

25. Shao C, Yang M, Pan Y, Xie D, Chen B, Ren S, et al. Case report: Abscopal effect of microwave ablation in a patient with advanced squamous NSCLC and resistance to immunotherapy. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.69749

26. Uchida R, Ohtsu Y, Nakamura K, Minayama K, Tanaka T, et al. Combined immunotherapy and radiotherapy for the patients with advanced stage of head and neck squamous cell carcinoma: a case report. Jpn J Clin Oncol (2017) 47(1):144–51. doi: 10.1093/jjco/hyw280

27. Lin X, Lu T, Xie Z, Qiu Y, Liu M, Xie X, et al. Extracranial abscopal effect induced by combined immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review. Thorac Cancer (2019) 10(5):1272–5. doi: 10.1111/1759-7714.13048

28. Craig et al. 10.3389/fonc.2022.987142
solid tumours: A proof-of-principle trial. Oncoimmunology (2014) 3:e28780.
doi: 10.4161/onci.28780

55. Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther (2017) 18(1):36–42. doi: 10.1080/15384047.2016.1264543

56. Slavin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase II/II study. Ann Oncol (2013) 24(7):1813–21. doi: 10.1093/annonc/mdt107

57. Kwon ED, Drake CG, Scher HI, Fizazi K, Rossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 15(7):700–12. doi: 10.1016/S1470-2045(14)70189-5

58. Shaverdan N, Lisberg AE, Bornaarz K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol (2017) 18(7):895–903. doi: 10.1016/S1470-2045(17)30380-7

59. Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Alumkal JJ, et al. Pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol (2017) 18(7):895–903. doi: 10.1016/S1470-2045(17)30380-7

60. Matty A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer (2018) 119(10):1200–7. doi: 10.1038/s41416-018-0281-9

61. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerriman M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial. Lancet Oncol (2015) 16(7):795–803. doi: 10.1016/S1470-2045(15)00054-6

62. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol (2009) 10(7):718–26. doi: 10.1016/S1470-2045(09)70082-8

63. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, et al. Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer. Clin Cancer Res (2018) 24(11):2493–504. doi: 10.1158/1078-0432.CCR-17-3322

64. Azad A, Yin Lim S, D’Costa Z, Jones K, Diana A, Sansom OJ, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med (2017) 9(2):167–80. doi: 10.15222/emmm.201606674

65. Dovedi SJ, Adlard A1, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res (2014) 74(19):5458–68. doi: 10.1158/0008-5472.CAN-14-1239

66. Doganah N, Kanaram S, Caglar HB, Oral EN. Abscopal effect of radiotherapy in the immunotherapy era: Systematic review of reported cases. Cureus (2019) 11(2):e4103. doi: 10.7759/cureus.4103

67. Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics (2021) 11(11):5365–86. doi: 10.7150/thno.58390

68. Maples P, Kumar P, Oxendine I, Jay C, Yiu Y, Kuhn J, et al. TAG vaccine: Autologous tumor vaccine genetically modified to express GM-CSF and block production of TGFβ2. BioProcess J (2009) 8(1):38–44. doi: 10.7150/bp.58390

69. Riester M, Wei W, Waldron I, Culhane AC, Trippa L, Oliva E, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst (2014) 106(5):38–44. doi: 10.1093/jnci/dju048

70. Robson H, et al. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer (1996) 74(5):753–8. doi: 10.1038/bjc.1996.432

71. Zhang M, Zhang YF, Chen Y, Wang J, Wang Q, Lu H. TGF-β signaling and resistance to cancer therapy. Front Cell Dev Biol (2021) 9:698. doi: 10.3389/fcell.2021.786728

72. Dranoff G, Jaffe E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U.S.A. (1993) 90(8):3539–43. doi: 10.1073/pnas.90.8.3539

73. Senzer N, Barve M, Kuhn J, Melynk A, Beitsch P, Lazar M, et al. Phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol Ther (2012) 20(3):679–86. doi: 10.1038/mnt.2011.269

74. Senzer N, Barve M, Nemunaitis J, Kuhn J, Melynk A, Beitsch P, et al. Long-term follow up: Phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG) in advanced cancer. J Vaccines Vaccination (2013) 4(8):209. doi: 10.3389/fonc.2022.987142